Market Overview

UPDATE: Brinson Patrick Initiates Vical at Market Outperform on Allovectin Potential

Related VICL
US Stock Futures Edge Higher Ahead Of Retail Sales, Jobless Claims Data
Vical Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial

In a report published Monday, Brinson Patrick analyst Vernon Bernardino initiated coverage on Vical (NASDAQ: VICL) with a Market Outperform rating and $7.00 price target.

In the report, Brinson Patrick noted, “We are initiating coverage of Vical with a Market Outperform rating and 12-month price target of $7. We believe Vical's lead product, Allovectin, is poised to be a significant driver of the company's shares, beginning in 2Q13 with database lock of its Allovectin in metastatic melanoma Phase III trial. We believe the results will be positive, positioning Vical with a blockbuster opportunity in the rapidly evolving melanoma market.”

Vical closed on Friday at $2.93.

Latest Ratings for VICL

DateFirmActionFromTo
Aug 2013CitigroupMaintainsBuy
Aug 2013Canaccord GenuityDowngradesBuyHold
Aug 2013Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for VICL
View the Latest Analyst Ratings

Posted-In: Brinson Patrick Vernon BernardinoAnalyst Color Initiation Analyst Ratings

 

Related Articles (VICL)

Around the Web, We're Loving...

Get Benzinga's Newsletters